AGEN earnings call for the period ending June 30, 2020.
News & Analysis: Agenus
The development-stage biopharma delivered two encouraging updates.
The immunotherapy company may be a diamond in the rough.
The biopharma company provided a clinical update for an important pipeline asset.
AGEN earnings call for the period ending March 31, 2020.
Agenus, Dynavax Technologies, and Verastem Oncology could all be outstanding picks for risk-tolerant investors.
These clinical-stage drugmakers could be a steal at current levels.
AGEN earnings call for the period ending December 31, 2019.
Results from an experimental combination therapy were impressive, but they might not be impressive enough.
The biopharma is scheduled to update investors and Wall Street analysts on two important pipeline programs on Feb. 20.